NEW YORK (360Dx) – With the advent of new cancer immunotherapies, and older such therapies being used for new indications, the use of PD-L1 testing to determine which patients may best respond to them has moved into the forefront of cancer care. 

But for clinicians facing a mottled molecular diagnostic landscape, deciding on the right test is hardly simple. The different tests may not be cross-compatible or interchangeable, and clinicians are forced to forage through complicated data and considerations for what they say should be a straightforward choice.